AARDEX Group

AARDEX Group announces the opening of a new office in the U.S.

By establishing itself in the U.S., the Group aims to strengthen its business and maintain its position as market leader in digital adherence monitoring systems.

Joe Keenan will lead the business development for the pharma and biotech industry in North America.

With over 70% of AARDEX’s customers based in the U.S., this new office will support local existing customers and help grow the U.S. market. 

“Our team is very excited about this next step”, said David Dalla Vecchia, CEO of AARDEX Group. “Our digital adherence monitoring solution is designed to fit the rapidly evolving needs to speed-up drug development for the pharmaceutical and biotech companies”. 

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,